Clarity have released results from their Phase II COBRA trial, evaluating their 64Cu-SAR-bisPSMA PET agent in prostate cancer (PCa) patients with suspected Biochemical Recurrence (BCR).
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.